Title
Category
Credits
Event date
Cost
Medication Assisted Treatments for Opiates, But What About Stimulants?
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
Telehealth for Substance Use
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, participants should be able to:
Pregnancy and Women’s SUD
  • S.U.D
  • Women's Health
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:After this course, participants should be able to:
Communication Matters: Motivational Interviewing and Substance Use Disorders
  • S.U.D
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
Screening and Identifying Opioid Use and Substance Use Disorders
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
The View from the Street: What FPs need to know about Fentanyl and Illicit Drugs
  • S.U.D
  • 1.00 AAFP Prescribed
$0.00
​Join Family Physician Rebecca Trotsky-Sirr and Sergeant Brian Gunsolley for a discussion of how patients are obtaining Fentanyl and other synthetic opioids and how physicians can help their patients recognize and understand the dangers of non-prescribed medication as well as encourage the use of reversal agents. In addition, resources will be provided to encourage more use of Medication Assisted Treatment.Learning Objectives:At the end of this session, learners should be able to:
MAT and Complex Patients: Addressing Provider Concerns
  • S.U.D
$0.00
Dr. San Bartolome provides case studies and information about managing care for complex patients with addictions who use more than one substance (polysubstance use).Learning Objectives:At the end of this session, learners should be able to:Identify key safety considerations when treating complex, polysubstance use cases for MAT, andExplain 2 strategies for addressing complicated inductions involving methadone and fentanyl.
Opioid and Substance Use Disorders in Special Populations: Youth and Young Adult Athletes
  • S.U.D
  • 1.25 AAFP Prescribed
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
Pain Management and Opioids: Balancing Risks and Benefits
  • S.U.D
  • Pain Management
  • 3.00 AAFP Prescribed
  • 3.00 AMA PRA Category 1 Credit™
$0.00
The curriculum, Pain Management and Opioids: Balancing Risks and Benefits, meets the latest FDA Blueprint and CDC guidelines for opioid prescribing and pain management, and includes the impact of COVID-19, new pain relieving treatments, and telehealth. This education includes California state-specific information and counts towards California CME requirements for pain management and opioid prescribing practices.This activity meets the new DEA CME requirement when renewing or obtaining your DEA license.
The Time for Treating Substance Use Disorder Is Now
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
People with substance use disorders (SUD) are coming to the office, whether we know it or not. Let's treat SUD/OUD (opioid use disorder) as we would treat any other medical condition: with compassion and good medicine. In this webinar you’ll learn to recognize stigma, communicate more effectively, and be more confident in choosing Medication for OUD (MOUD). Addiction medicine is family medicine.Learning Objective:At the end of this session, learners should be able to:Identify common barriers to health care practitioners beginning MOUD

Pages